Embryonic Stem Cell-Derived Neurons for Parkinson's: What the Landmark STEM-PD Trial Actually Found

On July 9, 2026, researchers from Lund University in Sweden and the University of Cambridge in the UK published the first 12-month results of STEM-PD, a Phase 1/2 trial that transplanted dopamine-producing nerve cells — grown in the lab from human embryonic stem cells — directly into the brains of people with moderate Parkinson's disease. This is one of the field's genuine milestones: real evidence that lab-grown replacement neurons can survive and begin functioning inside a human brain, with signs of clinical benefit in most participants. It's also a small, early trial with one serious complication that deserves equal weight. Here's what the data actually shows.

The Trial: Who, What, and How

STEM-PD enrolled eight participants with moderate Parkinson's disease (median age 63, median disease duration 14.5 years) at sites in Sweden and the UK, with cell transplants performed starting in October 2024. Each participant received dopamine progenitor cells — derived from human embryonic stem cells and matured toward becoming dopamine-producing neurons — surgically implanted into the putamen, the brain region most depleted of dopamine in Parkinson's disease. Participants were split across two dose levels and followed for 12 months on a course of immunosuppression to protect the transplanted cells from immune rejection, similar in principle to the immunosuppression used after an organ transplant.

The Primary Finding: The Cells Survive and Appear to Be Working

The trial's primary endpoint was safety and tolerability, and on the measure that matters most for a first-in-human cell transplant, the results are genuinely encouraging: no serious adverse events were attributed to the cell product itself, no graft-induced dyskinesias (involuntary movements that plagued some earlier-generation fetal-tissue transplant trials) were observed, and serial MRI scans showed no evidence of tumor formation — an important reassurance given that any therapy derived from stem cells carries a theoretical tumor risk. Dopamine-imaging PET scans showed increased tracer uptake in the treated brain region at 6 and 12 months, which the research team interprets as evidence that at least some transplanted cells survived and began functioning as dopamine-producing neurons — with one high-dose participant showing a 22.5% increase in signal. Six of the seven participants who completed follow-up substantially reduced their dopaminergic medication after the transplant, and clinical scores in the high-dose group improved on average at 12 months.

"Reaching this primary endpoint and being able to show that the cell product is safe is a great achievement," said Malin Parmar of Lund University, one of the trial's lead investigators. Gesine Paul-Visse of Skåne University Hospital added, "We are hopeful that the early signs of cell survival and clinical improvement we observe will continue to increase over time." Claire Bale, Associate Director of Research at Parkinson's UK, called the reduction in medication needs among six of seven participants "particularly encouraging" and the trial overall "a great milestone based on decades of work."

The Serious Complication, Reported Honestly

One participant died ten weeks after transplant from disseminated pulmonary aspergillosis, a fungal lung infection, while on the immunosuppression regimen required to protect the graft. The trial investigators were explicit that this death was not attributed to the cell product itself, but it is a real and serious outcome of the treatment protocol as a whole — immunosuppression carries a genuine, well-documented risk of opportunistic infection, and that risk did materialize in this trial. Researchers also reported 373 non-serious adverse events across participants, predominantly mild to moderate and mostly related to the immunosuppressive drugs rather than the cell transplant procedure itself. Any accurate account of this trial has to hold both facts together: the cell therapy component looks genuinely safe and biologically active, and the immunosuppression required to make that possible carries its own real risk, which proved fatal in one of eight participants.

Reading the Efficacy Data Honestly

The motor-score results were not uniformly positive: the low-dose group's median motor score (MDS-UPDRS Part III, measured with medication withheld) declined slightly at 12 months while the high-dose group improved by a median of 9 points, and the study's authors were candid that the magnitude of dopamine-signal increase seen with STEM-PD cells was still lower than what's been observed in some prior fetal-tissue transplant trials — suggesting dosing may need further optimization in future studies. No participant discontinued Parkinson's medication entirely, and none of the current cell-transplant approaches, including this one, has restored brain dopamine signal to a fully normal level. Parkinson's UK was careful to frame the results in proportion: "While this is a small trial with a relatively short follow-up period, and we will need to see longer-term results to get a better understanding of the impact, it represents a significant step forward."

Why This Trial Matters Beyond Parkinson's

STEM-PD is notable not just for Parkinson's disease specifically, but as a proof of concept for an entire category of regenerative medicine: using stem cell-derived, lab-grown replacement cells to treat degenerative disease by directly replacing what's been lost, rather than modulating symptoms. Earlier attempts to transplant fetal dopamine neurons into Parkinson's patients in the 1990s and 2000s showed the underlying concept could work but were limited by inconsistent cell sourcing and, in some cases, dyskinesia side effects; STEM-PD's use of a defined, lab-manufactured stem cell-derived product addresses the sourcing problem directly, and the absence of graft-induced dyskinesia in this trial is a meaningful improvement on that earlier history.

Bottom Line

STEM-PD is a real, peer-reviewed, methodologically serious milestone — an eight-person Phase 1/2 trial showing that stem cell-derived dopamine neurons can survive, show signs of function, and be associated with reduced medication need in most participants, twelve months after transplant. It is not evidence that this treatment is ready for wider use, is not FDA- or EMA-approved, and is not without serious risk — a participant died from an infection related to the immunosuppression the procedure requires. Anyone following this story, or considering any experimental cell-transplant trial, should ask: What is the trial's phase and how many participants have been followed, and for how long? What immunosuppression is required, and what are its own risks? And is this treatment available only within a registered, IRB-approved trial, or is someone offering something similar commercially? The genuine promise here is real — durable, long-term data from STEM-PD's continued follow-up, and larger confirmatory trials, are what will show whether it holds up.